Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 6/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110377 | 0.81 | MAPT (0.39) | MAPTHPGDSMN1; SMN2HSD17B10BRD4 | |
| SCHEMBL3271298 | 0.81 | KDM1A (0.38) | MAPTPOLBPKMLMNANPSR1 | |
| SCHEMBL3266936 | 0.79 | MAPT (0.37) | MAPTHPGDSMN1; SMN2POLBPKM | |
| SCHEMBL2908657 | 0.72 | MAPK10 (0.39) | MAPTHPGDSMN1; SMN2HSD17B10POLB | |
| SCHEMBL8902151 | 0.71 | HPGD (0.44) | MAPTHPGDSMN1; SMN2HSD17B10BRD4 | |
| SCHEMBL2906857 | 0.70 | ALDH1A1 (0.38) | MAPTSMN1; SMN2PKMLMNAMEN1 | |
| SCHEMBL3412817 | 0.70 | SMN1; SMN2 (0.42) | MAPTHPGDSMN1; SMN2HSD17B10BRD4 | |
| SCHEMBL3415258 | 0.68 | BRD4 (0.42) | MAPTHPGDSMN1; SMN2HSD17B10BRD4 | |
| SCHEMBL3431956 | 0.68 | ACHE (0.41) | MAPTHPGDSMN1; SMN2HSD17B10POLB | |
| SCHEMBL3431960 | 0.67 | CA1 (0.38) | MAPTHPGDSMN1; SMN2HSD17B10POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350028-B2 | 2-aminoquinolines | HOFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20090233927-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233927-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2B | MAPT 903/4885HPGD 2342/4885SMN1; SMN2 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.